* Benitec Biopharma Inc reported a quarterly adjusted loss of 48 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-2.76. The mean expectation of three analysts for the quarter was for a loss of 55 cents per share. Wall Street expected results to range from -67 cents to -44 cents per share.
* Reported revenue was zero; analysts expected zero.
* Benitec Biopharma Inc's reported EPS for the quarter was a loss of 48 cents.
* The company reported a quarterly loss of $5.06 million.
* Benitec Biopharma Inc shares had risen by 13.2% this quarter and gained 222.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 30% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Benitec Biopharma Inc is $20.00 This summary was machine generated from LSEG data November 15 at 02:06 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.55 -0.48 Beat
Jun. 30 2024 -0.49 -1.32 Missed
Mar. 31 2024 -0.78 -1.64 Missed
Dec. 31 2023 -0.39 -2.64 Missed
Comments